Annual Cash & Cash Equivalents
$194.61 M
-$82.17 M-29.69%
December 28, 2024
Summary
- As of February 23, 2025, CRL annual cash & cash equivalents is $194.61 million, with the most recent change of -$82.17 million (-29.69%) on December 28, 2024.
- During the last 3 years, CRL annual cash & cash equivalents has fallen by -$46.61 million (-19.32%).
- CRL annual cash & cash equivalents is now -29.69% below its all-time high of $276.77 million, reached on December 30, 2023.
Performance
CRL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
N/A
December 28, 2024
Summary
- CRL quarterly cash and cash equivalents is not available.
Performance
CRL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CRL Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -29.7% | - |
| 3 y3 years | -19.3% | - |
| 5 y5 years | -18.2% | - |
CRL Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.7% | at low | ||
| 5 y | 5-year | -29.7% | at low | ||
| alltime | all time | -29.7% | +1196.5% |
Charles River Laboratories International Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $194.61 M(-29.7%) | - |
| Sep 2024 | - | $210.17 M(+17.3%) |
| Jun 2024 | - | $179.21 M(-45.2%) |
| Mar 2024 | - | $327.04 M(+18.2%) |
| Dec 2023 | $276.77 M(+18.3%) | $276.77 M(+76.1%) |
| Sep 2023 | - | $157.17 M(-21.6%) |
| Jun 2023 | - | $200.44 M(-0.6%) |
| Mar 2023 | - | $201.59 M(-13.8%) |
| Dec 2022 | $233.91 M(-3.0%) | $233.91 M(+20.8%) |
| Sep 2022 | - | $193.70 M(-3.3%) |
| Jun 2022 | - | $200.32 M(-17.2%) |
| Mar 2022 | - | $241.87 M(+0.3%) |
| Dec 2021 | $241.21 M(+5.6%) | $241.21 M(+13.5%) |
| Sep 2021 | - | $212.54 M(-4.7%) |
| Jun 2021 | - | $222.97 M(-52.1%) |
| Mar 2021 | - | $465.41 M(+103.7%) |
| Dec 2020 | $228.42 M(-4.0%) | $228.42 M(-6.0%) |
| Sep 2020 | - | $242.88 M(-39.6%) |
| Jun 2020 | - | $402.02 M(+7.9%) |
| Mar 2020 | - | $372.43 M(+56.5%) |
| Dec 2019 | $238.01 M(+21.8%) | $238.01 M(+44.5%) |
| Sep 2019 | - | $164.76 M(-17.9%) |
| Jun 2019 | - | $200.59 M(+58.8%) |
| Mar 2019 | - | $126.32 M(-35.4%) |
| Dec 2018 | $195.44 M(+19.3%) | $195.44 M(+40.7%) |
| Sep 2018 | - | $138.87 M(-27.8%) |
| Jun 2018 | - | $192.30 M(+2.4%) |
| Mar 2018 | - | $187.77 M(+14.6%) |
| Dec 2017 | $163.79 M(+39.2%) | $163.79 M(+32.5%) |
| Sep 2017 | - | $123.62 M(+6.1%) |
| Jun 2017 | - | $116.47 M(-11.4%) |
| Mar 2017 | - | $131.52 M(+11.8%) |
| Dec 2016 | $117.63 M(-0.3%) | $117.63 M(+11.3%) |
| Sep 2016 | - | $105.72 M(-31.6%) |
| Jun 2016 | - | $154.59 M(-1.8%) |
| Mar 2016 | - | $157.38 M(+33.4%) |
| Dec 2015 | $117.95 M(-26.3%) | $117.95 M(+59.3%) |
| Sep 2015 | - | $74.03 M(-50.9%) |
| Jun 2015 | - | $150.81 M(-0.7%) |
| Mar 2015 | - | $151.92 M(-5.1%) |
| Dec 2014 | $160.02 M(+2.6%) | $160.02 M(+22.4%) |
| Sep 2014 | - | $130.75 M(+11.7%) |
| Jun 2014 | - | $117.01 M(-31.1%) |
| Mar 2014 | - | $169.85 M(+8.9%) |
| Dec 2013 | $155.93 M(+42.2%) | $155.93 M(+19.5%) |
| Sep 2013 | - | $130.45 M(+14.9%) |
| Jun 2013 | - | $113.52 M(+13.0%) |
| Mar 2013 | - | $100.42 M(-8.4%) |
| Dec 2012 | $109.69 M | $109.69 M(+31.8%) |
| Sep 2012 | - | $83.22 M(+9.4%) |
| Jun 2012 | - | $76.08 M(+24.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $61.03 M(-11.4%) |
| Dec 2011 | $68.91 M(-61.5%) | $68.91 M(-15.2%) |
| Sep 2011 | - | $81.22 M(-44.3%) |
| Jun 2011 | - | $145.83 M(-8.1%) |
| Mar 2011 | - | $158.75 M(-11.4%) |
| Dec 2010 | $179.16 M(-1.9%) | $179.16 M(+30.4%) |
| Sep 2010 | - | $137.43 M(-37.3%) |
| Jun 2010 | - | $219.08 M(-1.4%) |
| Mar 2010 | - | $222.20 M(+21.7%) |
| Dec 2009 | $182.57 M(-25.0%) | $182.57 M(-5.0%) |
| Sep 2009 | - | $192.20 M(+24.2%) |
| Jun 2009 | - | $154.81 M(-9.1%) |
| Mar 2009 | - | $170.23 M(-30.1%) |
| Dec 2008 | $243.59 M(+8.0%) | $243.59 M(+14.4%) |
| Sep 2008 | - | $212.85 M(-18.9%) |
| Jun 2008 | - | $262.44 M(+9.4%) |
| Mar 2008 | - | $239.88 M(+6.4%) |
| Dec 2007 | $225.45 M(+28.5%) | $225.45 M(+22.9%) |
| Sep 2007 | - | $183.50 M(+13.2%) |
| Jun 2007 | - | $162.05 M(+18.7%) |
| Mar 2007 | - | $136.54 M(-22.1%) |
| Dec 2006 | $175.38 M(+52.7%) | $175.38 M(-30.8%) |
| Sep 2006 | - | $253.50 M(+31.3%) |
| Jun 2006 | - | $193.07 M(+90.3%) |
| Mar 2006 | - | $101.46 M(-11.6%) |
| Dec 2005 | $114.82 M(-44.7%) | $114.82 M(-31.5%) |
| Sep 2005 | - | $167.71 M(+0.7%) |
| Jun 2005 | - | $166.55 M(-21.8%) |
| Mar 2005 | - | $213.06 M(+2.6%) |
| Dec 2004 | $207.57 M(+13.8%) | $207.57 M(-20.0%) |
| Sep 2004 | - | $259.41 M(+15.7%) |
| Jun 2004 | - | $224.15 M(+18.1%) |
| Mar 2004 | - | $189.75 M(+4.1%) |
| Dec 2003 | $182.33 M(+48.8%) | $182.33 M(+11.0%) |
| Sep 2003 | - | $164.32 M(+13.8%) |
| Jun 2003 | - | $144.34 M(+26.6%) |
| Mar 2003 | - | $114.01 M(-6.9%) |
| Dec 2002 | $122.51 M(+110.2%) | $122.51 M(+9.0%) |
| Sep 2002 | - | $112.39 M(+32.7%) |
| Jun 2002 | - | $84.71 M(-37.4%) |
| Mar 2002 | - | $135.40 M(+132.4%) |
| Dec 2001 | $58.27 M(+75.9%) | $58.27 M(-25.6%) |
| Sep 2001 | - | $78.30 M(+175.6%) |
| Jun 2001 | - | $28.42 M(-60.8%) |
| Mar 2001 | - | $72.40 M(+118.5%) |
| Dec 2000 | $33.13 M(+120.7%) | $33.13 M(+18.3%) |
| Sep 2000 | - | $28.01 M(+47.5%) |
| Jun 2000 | - | $18.99 M(+2.9%) |
| Mar 2000 | - | $18.46 M |
| Dec 1999 | $15.01 M(-39.5%) | - |
| Dec 1998 | $24.81 M | - |
FAQ
- What is Charles River Laboratories International annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Charles River Laboratories International?
- What is Charles River Laboratories International annual cash & cash equivalents year-on-year change?
- What is the all time high quarterly cash and cash equivalents for Charles River Laboratories International?
What is Charles River Laboratories International annual cash & cash equivalents?
The current annual cash & cash equivalents of CRL is $194.61 M
What is the all time high annual cash & cash equivalents for Charles River Laboratories International?
Charles River Laboratories International all-time high annual cash & cash equivalents is $276.77 M
What is Charles River Laboratories International annual cash & cash equivalents year-on-year change?
Over the past year, CRL annual cash & cash equivalents has changed by -$82.17 M (-29.69%)
What is the all time high quarterly cash and cash equivalents for Charles River Laboratories International?
Charles River Laboratories International all-time high quarterly cash and cash equivalents is $465.41 M